ADAM6 and acute lymphoblastic leukemia: It’s noteworthy here that no significant difference was found when comparing ADAM6 levels in ALL subtypes, T-ALL versus B-ALL patients (207.9 (173.5–391.0) and 211.1(170.3–320.0) pg/ml, p = 0.7022) as shown in Supplementary Figure S3.